Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
,
Lymphoma
,
Select Drug Profiles
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
Read More
FDA Approvals
,
Multiple Myeloma
,
Select Drug Profiles
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
,
Multiple Myeloma
,
Select Drug Profiles
FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Read More
FDA Approvals
,
Multiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
,
Lung Cancer
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
FDA Approvals
,
Lymphoma
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
FDA Approvals
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
Read More
FDA Approvals
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Read More
FDA Approvals
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
Read More
FDA Approvals
,
Select Drug Profiles
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer
Read More
9
10
11
12
13
14
15
Page 12 of 31
Results 111 - 120 of 305